Prediction of clinical events by liver stiffness and chronic kidney disease by NAFLD in patients with type-2 diabetes

Rivera-Esteban, Jesús; Pons, Mònica; Planas, Alejandra; Manzano-Nuñez, Ramiro; Hernández, Cristina; Simó-Servat, Olga; Bañeras, Jordi; Soler, María José; Seron, Daniel; Boixadera, Anna.
Gastroenterol. hepatol. (Ed. impr.) ; 46(9): 682-691, nov. 2023. tab, graf, ilus
Artigo em Inglês | IBECS (Espanha) | ID: ibc-226945

Documentos relacionados

  1. Comparative Burden of Metabolic Dysfunction in Lean NAFLD vs Non-lean NAFLD - A Systematic Review and Meta-analysis.
  2. Prediction of clinical events by liver stiffness and chronic kidney disease by NAFLD in patients with type-2 diabetes.
  3. Metabolic-associated fatty liver disease in relation to site-specific and multiple-site subclinical atherosclerosis.
  4. Sarcopenia Among Patients With Nonalcoholic Fatty Liver Disease (NAFLD) Is Associated With Advanced Fibrosis.
  5. Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.
  6. A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials.
  7. Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease.
  8. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults.
  9. The Spectrum and Impact of Metabolic Dysfunction in MAFLD: A Longitudinal Cohort Analysis of 32,683 Overweight and Obese Individuals.
  10. Incidence and Impact of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients with Adenocarcinoma of the Esophagus Treated with Curative Intent.